Endothelin Receptor Antagonists and Cardiovascular Diseases of Aging

[1]  D. Mann,et al.  Hemodynamic Effects of Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist, in Patients With Class III to IV Congestive Heart Failure , 2001, Circulation.

[2]  D. Badesch,et al.  Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  B. Prendergast,et al.  The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. , 2001, Journal of the American College of Cardiology.

[4]  D. Webb,et al.  Endothelin receptor antagonism in patients with chronic heart failure. , 2000, Cardiovascular research.

[5]  T. Lüscher,et al.  Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure , 2000 .

[6]  K. Gallagher,et al.  Chronic endothelin blockade in dogs with pacing-induced heart failure: possible modulation of sympathoexcitation. , 2000, Journal of cardiac failure.

[7]  D. Webb,et al.  Endothelins are potent vasoconstrictors, and much more besides. , 2000, Trends in pharmacological sciences.

[8]  B. Prendergast,et al.  Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. , 2000, Circulation.

[9]  L. Lerman,et al.  Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[10]  L. Ghiadoni,et al.  Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. , 1999, Circulation.

[11]  T. Lüscher,et al.  Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. , 1999, Circulation.

[12]  P. Thorén,et al.  Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Böhm,et al.  Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. , 1999, Circulation.

[14]  Y. Sugishita,et al.  Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. , 1999, Circulation.

[15]  G. Hasenfuss,et al.  Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. , 1999, Circulation.

[16]  D. Holmes,et al.  Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. , 1999, Circulation.

[17]  D. Fukai,et al.  Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. , 1999, Circulation.

[18]  R. Cannon,et al.  Role of endothelin in the increased vascular tone of patients with essential hypertension. , 1999, Hypertension.

[19]  M. Takaoka,et al.  Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. , 1999, Hypertension.

[20]  G. Slesak,et al.  Inotropic effects of endothelin-1: interaction with molsidomine and with BQ 610. , 1999, Hypertension.

[21]  T. Lüscher,et al.  Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Lüscher,et al.  Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. , 1998, Circulation.

[23]  P. Hunziker,et al.  Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. , 1998, Circulation.

[24]  J. Rouleau,et al.  Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. , 1998, Circulation.

[25]  M. Webb,et al.  The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure. , 1998, Journal of the American College of Cardiology.

[26]  Y. Kihara,et al.  Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. , 1998, Circulation.

[27]  P. Mulder,et al.  Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. , 1998, Cardiovascular research.

[28]  F. Barbe,et al.  Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs. , 1998, Cardiovascular research.

[29]  O. Smiseth,et al.  ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats. , 1998, American journal of physiology. Heart and circulatory physiology.

[30]  K. Münter,et al.  Endothelin and restenosis. , 1998, Cardiovascular research.

[31]  D. Stewart,et al.  Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. , 1998, Cardiovascular research.

[32]  D. Fukai,et al.  Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure. , 1998, Cardiovascular research.

[33]  J. Cleland,et al.  Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure , 1998, The Lancet.

[34]  C. Sotak,et al.  A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: a diffusion and perfusion MRI study. , 1998, Stroke.

[35]  H. Krum,et al.  The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. , 1998, The New England journal of medicine.

[36]  M. Redfield,et al.  Chronic oral endothelin type A receptor antagonism in experimental heart failure. , 1998, Hypertension.

[37]  D. Fukai,et al.  Chronic effects of a novel, orally active endothelin receptor antagonist, T-0201, in dogs with congestive heart failure. , 1998, Journal of cardiovascular pharmacology.

[38]  D. Stewart,et al.  Chronic endothelin-1 blockade preserves myocardial contractility in dilated cardiomyopathy. , 1998, Journal of cardiovascular pharmacology.

[39]  D. Webb,et al.  Endothelin: new discoveries and rapid progress in the clinic. , 1998, Trends in pharmacological sciences.

[40]  D. Stewart,et al.  Increased cardiac and pulmonary endothelin-1 mRNA expression in canine pacing-induced heart failure. , 1998, Journal of cardiovascular pharmacology.

[41]  T. Lüscher,et al.  ETA Receptor Blockade Prevents Increased Tissue Endothelin-1, Vascular Hypertrophy, and Endothelial Dysfunction in Salt-Sensitive Hypertension , 1998 .

[42]  A. Mimran,et al.  Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. , 1998, Hypertension.

[43]  B. Löffler,et al.  Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. , 1997, The Biochemical journal.

[44]  P. Galuppo,et al.  Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. , 1997, Circulation.

[45]  E. Braunwald.  Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.

[46]  D. Fukai,et al.  Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. , 1997, Journal of the American College of Cardiology.

[47]  T. Lüscher,et al.  Structure and function of small arteries in salt-induced hypertension: effects of chronic endothelin-subtype-A-receptor blockade. , 1997, Hypertension.

[48]  Y. Lampl,et al.  Endothelin in cerebrospinal fluid and plasma of patients in the early stage of ischemic stroke. , 1997, Stroke.

[49]  F. Lallemand,et al.  Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. , 1997, Circulation.

[50]  T. Lüscher,et al.  Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. , 1997, Circulation.

[51]  J. Granger,et al.  Role of endothelin in mediating the attenuated renal hemodynamics in Dahl salt-sensitive hypertension. , 1997, Hypertension.

[52]  E. Schiffrin,et al.  Effect of chronic ETA‐selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats , 1997 .

[53]  K. Gallagher,et al.  Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. , 1997, Circulation.

[54]  T. Lüscher,et al.  Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. , 1997, Hypertension.

[55]  B. Lipworth,et al.  Cardiopulmonary effects of endothelin-1 in man. , 1997, Cardiovascular research.

[56]  M. Komajda,et al.  Prognostic value of plasma endothelin-1 in patients with chronic heart failure. , 1997, European heart journal.

[57]  W. Edwards,et al.  Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. , 1997, Circulation.

[58]  E. Schiffrin,et al.  Enhanced expression of endothelin‐1 gene in resistance arteries in severe human essential hypertension , 1997, Journal of hypertension.

[59]  T. Lüscher,et al.  Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. , 1997, Hypertension.

[60]  Y. Sugishita,et al.  Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.

[61]  M. Maclean,et al.  EndothelinB receptor‐mediated contraction in human pulmonary resistance arteries , 1996, British journal of pharmacology.

[62]  D. Webb,et al.  Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. , 1996, Circulation.

[63]  D. Stewart,et al.  Human pulmonary circulation is an important site for both clearance and production of endothelin-1. , 1996, Circulation.

[64]  D. Heudes,et al.  Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. , 1996, Hypertension.

[65]  R. Mangiafico,et al.  Raised plasma endothelin-1 concentrations in patients with primary hypercholesterolemia without evidence of atherosclerosis. , 1996, International angiology : a journal of the International Union of Angiology.

[66]  S. Borzak,et al.  Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. , 1996, Circulation.

[67]  J. Kastrup,et al.  Plasma endothelin in congestive heart failure: a predictor of cardiac death? , 1996, Journal of cardiac failure.

[68]  P. Poole‐Wilson,et al.  Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. , 1996, Circulation.

[69]  D. Webb,et al.  Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. , 1996, Circulation.

[70]  J. McMurray,et al.  Endothelin in chronic heart failure: current position and future prospects. , 1996, Cardiovascular research.

[71]  K. Fujita,et al.  Effects of the endothelin ETA-receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. , 1996, Japanese journal of pharmacology.

[72]  S. Hosoda,et al.  Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. , 1996, Journal of the American College of Cardiology.

[73]  Y. Sugishita,et al.  Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. , 1996, Circulation.

[74]  D. Casellas,et al.  Preglomerular sudanophilia in L-NAME hypertensive rats: involvement of endothelin. , 1996, Hypertension.

[75]  D. Heistad,et al.  Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. , 1996, Hypertension.

[76]  J. Burnett,et al.  Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. , 1996, The Journal of clinical investigation.

[77]  D. Stewart,et al.  The pulmonary circulation is an important site for both clearance and production of endothelin-1 in humans , 1996 .

[78]  D. Heudes,et al.  Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. , 1996, Cardiovascular research.

[79]  M. Valentine,et al.  Orally Active Endothelin Receptor Antagonist BMS‐182874 Suppresses Neointimal Development in Balloon‐Injured Rat Carotid Arteries , 1995, Journal of cardiovascular pharmacology.

[80]  J. Stasch,et al.  Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. , 1995, American journal of hypertension.

[81]  D. Fukai,et al.  Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. , 1995, The American journal of cardiology.

[82]  M. Yano,et al.  EFFECTS OF A SELECTIVE ENDOTHELIN A‐RECEPTOR ANTAGONIST, BQ‐123, IN SALT‐LOADED STROKE‐PRONE SPONTANEOUSLY HYPERTENSIVE RATS , 1995, Clinical and Experimental Pharmacology and Physiology.

[83]  P. Hunziker,et al.  Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.

[84]  D. Webb,et al.  Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. , 1995, Circulation.

[85]  Meihong Lin,et al.  Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. , 1995, The Journal of clinical investigation.

[86]  F. Marumo,et al.  Nonselective ETA/ETB receptor antagonist blocks proliferation of rat vascular smooth muscle cells after balloon angioplasty. , 1995, Life sciences.

[87]  M. Kowala,et al.  Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. , 1995, The American journal of pathology.

[88]  M. Fujino,et al.  Pharmacology of a non‐selective ETA and ETB receptor antagonist, TAK‐044 and the inhibition of myocardial infarct size in rats , 1995, British journal of pharmacology.

[89]  A. Zeiher,et al.  Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. , 1995, Circulation.

[90]  A. Jeng,et al.  Inhibition of Big ET‐1-Induced Pressor Response by an Orally Active Dual Inhibitor of Endothelin‐Converting Enzyme and Neutral Endopeptidase 24.11 , 1995, Journal of cardiovascular pharmacology.

[91]  J. D. Elliott,et al.  The Endothelin Receptor Antagonist SB 217242 Reduces Cerebral Focal Ischemic Brain Injury , 1995, Journal of cardiovascular pharmacology.

[92]  J. Chalmers,et al.  Experimental hypertension produces diverse changes in the regional vascular responses to endothelin‐1 in the rabbit and the rat , 1994, Journal of hypertension.

[93]  F. Marumo,et al.  Three cases of malignant hypertension: the roles of endothelin-1 and the renin-angiotensin-aldosterone system. , 1994, Clinical nephrology.

[94]  D. Webb,et al.  Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. , 1994, British heart journal.

[95]  B. Löffler,et al.  Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). , 1994, Circulation.

[96]  D. Webb,et al.  Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. , 1994, The Journal of clinical investigation.

[97]  D. Webb,et al.  Contribution of endogenous generation of endothelin-1 to basal vascular tone , 1994, The Lancet.

[98]  M. Yanagisawa,et al.  ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1 , 1994, Cell.

[99]  T. Rabelink,et al.  Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. , 1994, Kidney international.

[100]  E. Schiffrin,et al.  Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. , 1994, Hypertension.

[101]  Benjamin Sovacool,et al.  Heart Disease, Cancer, and Stroke Mortalit Trends And Their Interrelations: An International Perspective , 1994, Circulation.

[102]  S. Douglas,et al.  BQ‐123, a selective endothelin subtype A‐receptor antagonist, lowers blood pressure in different rat models of hypertension , 1994, Journal of hypertension.

[103]  J. Winkles,et al.  Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. , 1994, The Journal of biological chemistry.

[104]  R. T. Lie,et al.  Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. , 1994, Circulation.

[105]  S. Ozaki,et al.  Clearance of circulating endothelin-1 by ETB receptors in rats. , 1994, Biochemical and biophysical research communications.

[106]  S. S. Sørensen,et al.  Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. , 1994, The American journal of physiology.

[107]  L. V. von Segesser,et al.  Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. , 1994, Circulation.

[108]  P. Vallance,et al.  Endothelin receptors mediating functional responses in human small arteries and veins , 1994, British journal of pharmacology.

[109]  A. Davenport,et al.  Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? , 1994, Trends in pharmacological sciences.

[110]  A. Carayon,et al.  Plasma endothelin and pulmonary pressures in patients with congestive heart failure. , 1993, American heart journal.

[111]  W. Neidhart,et al.  Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist , 1993, Nature.

[112]  D. Kohan.  Endothelins in the kidney: physiology and pathophysiology. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[113]  G. Grover,et al.  The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. , 1993, Cardiovascular research.

[114]  A. Nogami,et al.  Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. , 1993, The Journal of clinical investigation.

[115]  P. Vanhoutte,et al.  Is endothelin involved in the pathogenesis of hypertension? , 1993, Hypertension.

[116]  D. Webb,et al.  The endothelin family of peptides: local hormones with diverse roles in health and disease? , 1993, Clinical science.

[117]  M. Mulvany,et al.  Small artery structure in hypertension. Dual processes of remodeling and growth. , 1993, Hypertension.

[118]  M. Yano,et al.  Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. , 1993, Life sciences.

[119]  M. Kohzuki,et al.  Endothelin-1 augments pressor response to angiotensin II infusion in rats. , 1992, Hypertension.

[120]  B. Binder,et al.  Polar secretion of endothelin-1 by cultured endothelial cells. , 1992, The Journal of biological chemistry.

[121]  R. Rodeheffer,et al.  Increased plasma concentrations of endothelin in congestive heart failure in humans. , 1992, Mayo Clinic proceedings.

[122]  A. Achiron,et al.  Increased Plasma Endothelin‐1 in Acute Ischemic Stroke , 1992, Stroke.

[123]  T. Lüscher,et al.  Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. , 1992, Circulation research.

[124]  E. Schiffrin,et al.  Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients. , 1992, Journal of hypertension.

[125]  J. McMurray,et al.  Circulating endothelin in acute ischaemic syndromes. , 1992, British heart journal.

[126]  W. Waldhäusl,et al.  Regional effects and clearance of endothelin‐1 across pulmonary and splanchnic circulation , 1992, European journal of clinical investigation.

[127]  J. McMurray,et al.  Plasma Endothelin in Chronic Heart Failure , 1992, Circulation.

[128]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[129]  T. Schaberg,et al.  Endothelin increases [Ca2+]i, protein phosphorylation, and O2-. production in human alveolar macrophages. , 1991, The American journal of physiology.

[130]  A. Lerman,et al.  Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. , 1991, The New England journal of medicine.

[131]  Y. Dohi,et al.  Endothelin in Hypertensive Resistance ArteriesIntraluminal and Extraluminal Dysfunction , 1991, Hypertension.

[132]  T. Horio,et al.  Increased plasma immunoreactive endothelin-1 concentration in hypercholesterolemic rats. , 1991, Atherosclerosis.

[133]  T. Watanabe,et al.  Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. , 1991, Circulation research.

[134]  D. Webb,et al.  Pharmacology of endothelin-1 in vivo in humans. , 1991, Journal of Cardiovascular Pharmacology.

[135]  S. Nakanishi,et al.  Cloning and expression of a cDNA encoding an endothelin receptor , 1990, Nature.

[136]  T. Sakurai,et al.  Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor , 1990, Nature.

[137]  H. Yasuda,et al.  Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. , 1990, Journal of molecular and cellular cardiology.

[138]  L. V. von Segesser,et al.  Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? , 1990, Circulation.

[139]  M. Rand,et al.  MECHANISMS OF THE EFFECTS OF ENDOTHELIN ON RESPONSES TO NORADRENALINE AND SYMPATHETIC NERVE STIMULATION , 1990, Clinical and experimental pharmacology & physiology.

[140]  R. O. Banks,et al.  Cardiorenal actions of endothelin, Part I: Effects of converting enzyme inhibition. , 1990, Life sciences.

[141]  D. Webb,et al.  Endothelin is a potent long-lasting vasoconstrictor in men. , 1989, The American journal of physiology.

[142]  M. Clozel.  Endothelin sensitivity and receptor binding in the aorta of spontaneously hypertensive rats. , 1989, Journal of hypertension.

[143]  Y. Sugishita,et al.  Characteristics of Pressor Response to Endothelin in Spontaneously Hypertensive and Wistar‐Kyoto Rats , 1989, Hypertension.

[144]  Y. Hirata,et al.  Endothelin is a potent mitogen for rat vascular smooth muscle cells. , 1989, Atherosclerosis.

[145]  M. Yanagisawa,et al.  The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[146]  T. Ogihara,et al.  Endothelin enhances adrenergic vasoconstriction in perfused rat mesenteric arteries. , 1989, Biochemical and biophysical research communications.

[147]  M. Boarder,et al.  Characterization of Endothelin‐1 Stimulation of Catecholamine Release from Adrenal Chromaffin Cells , 1989, Journal of cardiovascular pharmacology.

[148]  J. Vane,et al.  Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[149]  Y. Yazaki,et al.  Endothelin stimulates c‐fos and c‐myc expression and proliferation of vascular smooth muscle cells , 1988, FEBS letters.

[150]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[151]  Bridget Wilcken,et al.  The pathogenesis of coronary artery disease , 1976 .